文献速递神经免疫

多发性硬化症治疗中芬戈莫德、那他珠单抗、利妥昔单抗与注射疗法的感染风险

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
PubMed 文献 · JAMA Neurol · 2020-01-01

结果显示利妥昔单抗的严重感染率最高(粗发生率19.7/1000人年),调整后风险仍显著高于干扰素β/醋酸格拉替雷(HR 1.70),而芬戈莫德和那他珠单抗调整后风险无显著差异。

要点

  • 多发性硬化症患者总体感染风险高于一般人群。
  • 利妥昔单抗治疗者严重感染风险显著高于干扰素β/醋酸格拉替雷。
  • 芬戈莫德和那他珠单抗调整后严重感染风险无显著增加。

核心结论

  • 多发性硬化症患者感染风险总体增加,且因治疗不同而异。
  • 利妥昔单抗与最高的严重感染率相关,干扰素β/醋酸格拉替雷最低。

研究设计与样本

  • 瑞典全国登记队列研究,2011年1月1日至2017年12月31日。

主要发现

  • 干扰素β/醋酸格拉替雷组粗感染发生率为8.9/1000人年(95%CI 6.4-12.1),一般人群为5.2/1000人年(95%CI 4.8-5.5)。
  • 芬戈莫德组粗发生率为14.3/1000人年(95%CI 10.8-18.5),那他珠单抗组为11.4/1000人年(95%CI 8.3-15.3),利妥昔单抗组为19.7/1000人年(95%CI 16.4-23.5)。
  • 与干扰素β/醋酸格拉替雷相比,调整后利妥昔单抗的严重感染风险仍显著升高(HR 1.70,95%CI 1.11-2.61)。
  • 芬戈莫德(HR 1.30,95%CI 0.84-2.03)和那他珠单抗(HR 1.12,95%CI 0.71-1.77)调整后风险无显著差异。
  • 抗疱疹药物使用:利妥昔单抗与干扰素β/醋酸格拉替雷相似,低于那他珠单抗(HR 1.82,95%CI 1.34-2.46)和芬戈莫德(HR 1.71,95%CI 1.27-2.32)。

临床怎么用

  • 临床决策中应考虑不同疾病修饰治疗对严重感染风险的影响。
  • 使用利妥昔单抗时需警惕严重感染风险,权衡获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk increase is not well established in real-world populations. Even less is known about infection risk associated with rituximab, which is extensively used off-label to treat MS in Sweden. OBJECTIVE: To examine the risk of serious infections associated with disease-modifying treatments for MS. DESIGN, SETTING, AND PARTICIPANTS: This nationwide register-based cohort study was conducted in Sweden from January 1, 2011, to December 31, 2017. National registers with prospective data collection from the public health care system were used. All Swedish patients with relapsing-remitting MS whose data were recorded in the Swedish MS register as initiating treatment with rituximab, natalizumab, fingolimod, or interferon beta and GA and an age-matched and sex-matched general population comparator cohort were included. EXPOSURES: Treatment with rituximab, natalizumab, fingolimod, and interferon beta and GA. MAIN OUTCOMES AND MEASURES: Serious infections were defined as all infections resulting in hospitalization. Additional outcomes included outpatient treatment with antibiotic or herpes antiviral medications. Adjusted hazard ratios (HRs) were estimated in Cox regressions. RESULTS: A total of 6421 patients (3260 taking rituximab, 1588 taking natalizumab, 1535 taking fingolimod, and 2217 taking interferon beta/GA) were included, plus a comparator cohort of 42 645 individuals. Among 6421 patients with 8600 treatment episodes, the mean (SD) age at treatment start ranged from 35.0 (10.1) years to 40.4 (10.6) years; 6186 patients were female. The crude rate of infections was higher in patients with MS taking interferon beta and GA than the general population (incidence rate, 8.9 [95% CI, 6.4-12.1] vs 5.2 [95% CI, 4.8-5.5] per 1000 person-years), and higher still in patients taking fingolimod (incidence rate, 14.3 [95% CI, 10.8-18.5] per 1000 person-years), natalizumab (incidence rate, 11.4 [95% CI, 8.3-15.3] per 1000 person-years), and rituximab (incidence rate, 19.7 [95% CI, 16.4-23.5] per 1000 person-years). After confounder adjustment, the rate remained significantly higher for rituximab (HR, 1.70 [95% CI, 1.11-2.61]) but not fingolimod (HR, 1.30 [95% CI, 0.84-2.03]) or natalizumab (HR, 1.12 [95% CI, 0.71-1.77]) compared with interferon beta and GA. In contrast, use of herpes antiviral drugs during rituximab treatment was similar to that of interferon beta and GA and lower than that of natalizumab (HR, 1.82 [1.34-2.46]) and fingolimod (HR, 1.71 [95% CI, 1.27-2.32]). CONCLUSIONS AND RELEVANCE: Patients with MS are at a generally increased risk of infections, and this differs by treatment. The rate of infections was lowest with interferon beta and GA; among newer treatments, off-label use of rituximab was associated with the highest rate of serious infections. The different risk profiles should inform the risk-benefit assessments of these treatments.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020. PMID: 31589278. doi:10.1001/jamaneurol.2019.3365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。